Future Outlook: Innovations in Obesity and Diabetes Treatments The future of obesity and diabetes care will likely include: Combination therapies (GLP-1 + amylin analogs)
A less common but possible side effect, due to its breakdown into trimethylamine
Diabetes Ther 9 (Suppl 1), 142 (2018)
In a phase 2, multicenter, randomized, placebo controlled double blind study, crizanlizumab with or without hydroxyurea (SUSTAIN study) (ClinicalTrails.gov Identifier: NCT01895361) showed that patients on the treatment arm had significantly lower rate of sickle-related pain crises compared to placebo with a lower incidence of adverse events - 10% of patients suffered from moderate side effects while one patient suffered from an intracranial bleed during treatment with this drug that could also interfere with platelet function via its effects on selectins ( Post hoc analyses showed that more patients were VOC event-free in the crizanlizumab arm than in the placebo arm, and that crizanlizumab also significantly increased time-to-first VOC compared to the placebo (Kutlar et al., 2019)
Concentrate on problem areas such as the cheeks and forehead
Even if you dont get migraine headaches, you probably know someone who does
